Press Releases
Study Demonstrates People Living with Type 2 Diabetes and Obesity Can Be Successfully Treated with GI Dynamics' EndoBarrierTM Gastrointestinal Liner for 12 Months
GI Dynamics' EndoBarrierTM Gastrointestinal Liner to be Highlighted
at Upcoming Cleveland Clinic ConferenceGI Dynamics Receives Strategic Investment from Medtronic, Inc.
GI Dynamics Receives European CE Mark Approval for the EndoBarrierTM Gastrointestinal Liner System for the Treatment of Type 2 Diabetes and Obesity
Interim Data from a Clinical Trial Evaluating GI Dynamics' EndoBarrierTM Gastrointestinal Liner in Patients with Type 2 Diabetes Presented at GASTRO 2009
GI Dynamics' EndoBarrierTM Gastrointestinal Liner Demonstrates Significant HbA1c Reduction in Obese People Living with Type 2 Diabetes
GI Dynamics' EndoBarrier™ Gastrointestinal Liner Demonstrates Safety and Efficacy in Pre-surgical Weight Loss
Data from a Clinical Study Evaluating GI Dynamics’ EndoBarrier to be Presented at IFSO
Novel Non-Surgical Therapy Dramatically Increases Weight Loss in Obese Patients; Results from Pilot Clinical Study Presented at ASMBS
GI Dynamics' EndoBarrier™ Gastrointestinal Liner to be Highlighted at Several Prominent International Diabetes and Obesity Meetings
GI Dynamics Closes an Additional $15 Million in Series C Financing
GI Dynamics Receives ISO Certification and European CE Mark Approval for the EndoBarrier™ Gastrointestinal Liner System
New Data in Journal Obesity Demonstrate that a Noninvasive, Removable Medical Device Results in Substantial Weight Loss and Glucose Normalization in a Preclinical Model of Obesity
GI Dynamics Announces Promising Multi-Center Safety and Efficacy Data of EndoBarrier™ Gastrointestinal Liner for Pre-Surgical Weight Loss
GI Dynamics Announces Data Demonstrating Immediate and Sustained Reduction in HbA1c in Patients with Type 2 Diabetes Using EndoBarrier™ Gastrointestinal Liner
Initial Results of GI Dynamics's EndoBarrier Presented at American Diabetes Association Conference